arGEN-X, a Rotterdam, The Nederlands-based biopharmaceutical company focused on the discovery and development of human monoclonal antibodies, has received a €1.3m grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
The company intends to use the funding to further advance its discovery platform (SIMPLE Antibody™platform), designed to enable the production of multiple novel and diverse leads against complex soluble, cell surface and highly conserved targets.
arGEN-X’ most advanced program, ARGX-110, addresses a clinically validated cell surface receptor implicated in autoimmunity and cancer and has been shown in preclinical models to modulate target function with unrivalled potency. The company expects to file an IND application for ARGX-110 in early 2013.
Related News: arGEN-X Closes €27.5M Series B Funding Round